Hawthorn's Roughead begins immunotherapy treatment

Edit Australian Broadcasting Corporation 07 Jun 2016
Hawthorn's Jarryd Roughead begins immunotherapy treatment after being diagnosed with a recurrence of melanoma ... ....

A New Immunotherapy against Cancer Earns a Hebrew University Researcher the Kaye Innovation Award (Hebrew University of Jerusalem)

Edit Public Technologies 07 Jun 2016
(Source. Hebrew University of Jerusalem). The importance of the body's immune system in protecting against the creation of cancerous tumors has been known for a long time ... A major goal of cancer immunotherapy is to generate, induce or augment an anti-tumor immune response ... Dr ... Dr ... Additionally, these mAbs can act synergistically with existing immunotherapies, such as anti-PD1, anti-PD1L and anti-CTLA4 ... photo credit. Douglas Guthrie ... (noodl....

NEW STORY CEL-SCI to Present at LD Micro Invitational (CEL-SCI Corporation)

Edit Public Technologies 07 Jun 2016
CVM), a late-stage cancer immunotherapy company, announced today that it will be presenting at the 6th annual LD Micro Invitational on Wednesday, June 8th at 10.30 AM PST / 1.30 PM EST ... CEL-SCI believes that we should give the immune system the best chance of successfully fighting cancer by administering a cancer immunotherapy drug before surgery, radiation and chemotherapy, a time when the immune system is thought to be strongest....

ImmunoCellular Therapeutics Treats First Patient in ICT-107 Phase 3 Registrational Trial in Newly Diagnosed Glioblastoma (ImmunoCellular Therapeutics Ltd)

Edit Public Technologies 07 Jun 2016
IMUC) today announced that the first patient has been treated in the phase 3 registrational trial of ICT-107, the Company's lead cancer immunotherapy product candidate, in newly diagnosed glioblastoma. ICT-107 is a patient-specific, dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells....

Roswell Park Launches Global Biotechnology & Cancer Therapeutics at BIO International Convention in San Francisco, CA (Roswell Park Cancer Institute)

Edit Public Technologies 07 Jun 2016
'GBCT will allow outside biotechnology companies to partner with a scientifically respected entity that will provide infrastructure for drug development and investment - everything from clinical trials to anticancer agents and vaccines, cellular therapies, immunotherapies and surgical devices,' says GBCT's Chief Operating Officer, David Donovan, who is also Senior Executive Director of Business Development at Roswell Park....

Launch of a non-interventional study in hepatocellular carcinoma (OSE Immunotherapeutics SA)

Edit Public Technologies 07 Jun 2016
OSE), an immuno-oncology company with a specific immunotherapy activating T lymphocytes, currently in a registration Phase 3 study, and Effimune, a biotech company specialized in immune regulation with clinical applications in autoimmunity, transplantation and immune-oncology, today announce the launch of a non-interventional study in patients with hepatocellular carcinoma (primary liver cancer)....

The Future of Cancer Treatments: Immunotherapies and Novel Pathways and Their CV Effects (American College of Cardiology Foundation)

Edit Public Technologies 07 Jun 2016
As novel immunotherapies come to market, awareness of cardiac toxicities will become increasingly important as the indications for immune checkpoint inhibitors continue to expand ... CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells....

Aimmune Therapeutics Announces Late-Breaker Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2016 (Aimmune Therapeutics Inc)

Edit Public Technologies 07 Jun 2016
AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today announced that ... The safety and tolerability of AR101, an oral immunotherapy (OIT) pharmaceutical formulation for peanut allergy, after more than one year of treatment (abstract #2 362)....

Hawthorn Hawks' Jarryd Roughead begins cancer treatment

Edit Canberra Times 07 Jun 2016
Jarryd Roughead on Tuesday began a year-long course of immunotherapy to treat spots of cancer on his lungs, with his wife by his side ... ....

Superior Results for Myeloma Drug That's Added Earlier in Treatment

Edit The Indiana Times 07 Jun 2016
MONDAY, June 6, 2016 (HealthDay News) -- A recently approved immunotherapy drug for a blood cancer called multiple myeloma can provide even better benefits if patients receive it earlier in their treatment, new clinical trial results show ... ....

CEO Frank Bedu-Addo Presenting at BIO 2016

Edit PR Newswire 07 Jun 2016
NORTH BRUNSWICK, N.J., June 7, 2016 /PRNewswire/ -- PDS Biotechnology, a private clinical stage immuno-oncology company developing novel immunotherapies, announces that CEO Frank Bedu-Addo will make a presentation at BIO 2016, being held at the Moscone Center, 747 Howard Street, San ... ....

ImmunoCellular Therapeutics Treats First Patient in ICT-107 Phase 3 Registrational Trial in Newly Diagnosed Glioblastoma

Edit PR Newswire 07 Jun 2016
LOS ANGELES, June 7, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT. IMUC) today announced that the first patient has been treated in the phase 3 registrational trial of ICT-107, the Company's lead cancer immunotherapy product candidate, in newly ... ....

TapImmune Announces Finalization of License Agreement With Mayo Clinic to Commercialize a HER2neu Vaccine

Edit PR Newswire 07 Jun 2016
JACKSONVILLE, Florida, June 7, 2016 /PRNewswire/ -- TapImmune, Inc. (OTCQB. TPIV), a clinical stage cancer immunotherapy company is pleased to announce that the Company has exercised its option agreement with Mayo Clinic and signed a worldwide license agreement to a proprietary HER2neu... ....
×